[Systematic review and meta-analysis of clinical trials of the efficacy and safety of ipidacrine for the treatment of peripheral neuropathies].

Authors

A V Amelin, S A Zhivolupov, N A Suponeva, V N Khramilin

Published in

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. Volume 126. Issue 2. Pages 68-76.

Abstract

To evaluate the efficacy and safety of adding ipidacrine to the therapy of patients with peripheral neuropathies (PN) of any etiology.
A systematic review and meta-analysis of clinical trials evaluating the efficacy and safety of ipidacrine in patients with PN from 2000 to 2025 was conducted. Based on four database searches, 12 studies involving 4.309 adult patients were included in the analysis. The outcomes evaluated included the dynamics of pain intensity, neurophysiological parameters according to the results of electroneuromyography, and safety parameters.
Statistically significant superiority of ipidacrine over comparison therapy in reducing pain intensity on a visual analogue scale at 2 (mean difference [MD] 6.16, 95% confidence interval [CI] 2.30; 10.02, p=0.002) and 8 weeks (MD 8.59, 95% CI 1.46; 15.73, p=0.018), as well as on a digital rating scale at 4 weeks (MD 1.10, 95% CI 0.18; 2.02, p=0.02). The increase in the velocity of the pulse along the peripheral motor fibers after 6 weeks during ipidacrine therapy was statistically significantly greater than during comparison therapy (MD -4.08, 95% CI -5.63; -2.53, p<0.001). A statistically significant superiority of ipidacrine therapy was noted in terms of a decrease in the neuropathic dysfunctional score at 8 weeks (p=0.007), the frequency of pain reduction at 2 weeks (p=0.032). There was no clinically significant increase in the incidence of adverse events when ipidacrine was added to therapy.
Ipidacrine is an effective and safe component of complex therapy of PN, promotes pain relief, improved nerve conduction and functional recovery with good tolerance.

PMID:
41782533
Bibliographic data and abstract were imported from PubMed on 05 Mar 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.